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ABSTRACT
After injury, regrowth of axons in mammalian adult central nervous system is highly
limited. However, in monkeys subjected to unilateral cervical lesion (C7–C8 level), neutral-
ization of an important neurite outgrowth inhibitor, Nogo-A, stimulated axonal sprouting
caudal to the lesion, accompanied by enhanced functional recovery of manual dexterity,
compared with lesioned monkeys treated with a control antibody (Freund et al. [2006] Nat.
Med. 12:790–792). The present study aimed at comparing the same two groups of monkeys
for axonal sprouting rostral to the cervical lesion. The corticospinal tract was labeled by
injecting the anterograde tracer biotinylated dextran amine into the contralesional motor
cortex. The corticospinal axons were interrupted at the level of the lesion, accompanied by
retrograde axonal degeneration (axon dieback), reﬂected by the presence of terminal retrac-
tion bulbs. The number of terminal retraction bulbs was lower in anti-Nogo-A antibody
treated monkeys, and, when present, they were found closer to the lesion than in control-
antibody treated monkeys. Compared with control antibody treated monkeys, the anti-
Nogo-A antibody treated monkeys exhibited an increased cumulated axon arbor length and
a higher number of axon arbors going in the medial direction from the white to the gray
matter. Higher in the cervical cord (at C5 level), the anti-Nogo-A treatment enhanced the
number of corticospinal ﬁbers crossing the midline, suggesting axonal sprouting. Thus, the
anti-Nogo-A antibody treatment enhanced axonal sprouting rostral to the cervical lesion;
some of these ﬁbers grew around the lesion and into the caudal spinal segments. These
processes paralleled the observed improved functional recovery.
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After spinal cord injury, the regrowth of injured axons
in the adult mammalian central nervous system (CNS) is
extremely limited. Immediately after onset of injury, a
series of structural changes occurs proximal and distal to
the point of transection. Whereas the distal stump of the
axon degenerates, corresponding to the so-called Walle-
rian degeneration, the proximal stump of the axon dies
back (i.e., retracts) by several hundreds micrometers, as
observed for example in the corticospinal (CS) tract of
mice (Kerschensteiner et al., 2005). A typical feature of
the transected axonal stumps proximal to the lesion is the
formation of a terminal retraction bulb (Kalil and Schnei-
der, 1975; Kao et al., 1977a,b; Houle and Jin, 2001).
The fate of axotomized CS neurons in the monkey is
controversial, with claims of signiﬁcant loss (see, e.g.,
Holmes and May, 1909; Wohlfarth, 1932; Levin and Brad-
ford, 1938; Pernet and Hepp-Reymond, 1975), contrasting
with evidence for survival of most CS neurons (Tower,
1940; Lassek, 1948). In a recent study, we conﬁrmed that
most CS neurons survived the axotomy, but their soma
shrink (Wannier et al., 2005). In spite of the survival of
their cell body, only a very limited regrowth of injured
nerve ﬁbers may take place in the adult mammalian CNS
because of the presence of neurite outgrowth inhibitors,
such as Nogo-A (see, e.g., Caroni et al., 1988; Schwab,
2004), within the CNS myelin. In fact, a therapeutic ap-
proach based on the application of antibodies neutralizing
Nogo-A resulted in enhanced regrowth or regenerative
sprouting of CS axons following spinal cord lesion in rats
(see, e.g., Schnell and Schwab, 1990; Bregman et al., 1995;
Thallmair et al., 1998; Bro¨samle et al., 2000; Liebscher et
al., 2005; for review see Schwab, 2004), in marmosets
(Fouad et al., 2004), and in macaque monkeys (Freund et
al., 2006). Compared with animals also subjected to a
spinal cord lesion and treated with a control antibody, the
anti-Nogo-A antibody treatment promoted sprouting of CS
axons caudal to the lesion, in the area of denervated
motoneuron pools. In rats (Bregman et al., 1995; Thall-
mair et al., 1998; Schwab, 2004; Liebscher et al., 2005)
and macaque monkeys (Freund et al., 2006), the sprouting
of CS axons caudal to the lesion, promoted by anti-Nogo-A
antibody treatment, was paralleled by an enhancement of
functional motor recovery for various speciﬁc behavioral
tasks, even leading to a complete recovery of performance
on some of them.
Given that the regrowth of CS ﬁbers caudal to a cervical
spinal lesion occurred in parallel with better functional
recovery of the hand in monkeys (Freund et al., 2006), the
aim of the present study was to investigate, anatomically,
how a cervical cord hemisection affects the CS axons ros-
tral to the lesion in terms of dieback and formation of
terminal retraction bulbs (see Fig. 1A). A speciﬁc goal was
to assess whether the anti-Nogo-A antibody treatment
may reduce or prevent axonal retraction effects proximal
to the lesion and, in addition, favor local axonal sprouting.
Thirteen macaque monkeys were therefore subjected to a
cervical cord lesion unilaterally interrupting the dorsolat-
eral funiculus; seven monkeys were treated with an anti-
Nogo-A antibody, whereas the other six received a control
antibody. The anterograde labeling of CS axons originat-
ing from the contralesional hemisphere, allowed us to
address the following issues: 1) Does the proximal part of
the axotomized CS axons retract from the lesion? If yes, in
what proportion of CS axotomized axons does such a re-
traction occur and what is the distance of retraction? Does
anti-Nogo-A antibody treatment prevent such retraction
of CS axons? 2) Do some axotomized CS axons attempt to
reapproach and eventually enter the lesion? If yes, does
the anti-Nogo-A antibody treatment make such attempts
more successful? 3) Above the cervical lesion, do the axo-
tomized CS axons sprout, giving rise to collaterals medi-
ally into the gray matter and/or growing around the le-
sion, thus possibly contributing to the enhanced presence
of CS axons observed caudal to the lesion in anti-Nogo-A
antibody treated monkeys (Freund et al., 2006)?
MATERIALS AND METHODS
Animals
The experiments were conducted on 16 adult macaque
monkeys (Macaca mulatta and M. fascicularis; see Tables
1, 2; see also Supplementary Table 1 in Freund et al.,
2006) of either sex. Surgical procedures and animal care
were conducted in accordance with the NIH Guide for the
care and use of laboratory animals (ISBN 0-309-05377-3;
1996) and were approved by local (Swiss) veterinary au-
thorities. Conditions for housing of the animals as well as
the behavioral procedures aimed at assessing the manual
dexterity of monkeys before and after the lesion were
described in detail earlier (Schmidlin et al., 2004, 2005;
Freund et al., 2006). Only the methods speciﬁcally rele-
vant for the present study will be described below in
detail. Among the 16 monkeys, 13 were subjected to a
unilateral cervical cord lesion (see below). The lesioned
monkeys were 3.5–6.9 years old at time of death, thus
corresponding to young adult monkeys, and their weight
ranged from 3.0 to 5.0 kg. The other three monkeys (see
Table 2 for age and weight) were intact and were consid-
ered here for comparison of some tracing data (see Fig.
5E,F) with the lesioned monkeys. One of the three intact
monkeys was used in a previous tracing study describing
the CS projection originating from the primary motor cor-
tex (Rouiller et al., 1996).
Surgical procedures: unilateral lesion of the
dorsolateral funiculus
In 13 monkeys, a unilateral cervical cord lesion was
performed as follows. Intramuscular injection of ketamine
(Ketalar; Parke-Davis; 5 mg/kg, i.m.) was performed to
induce anesthesia, and atropine was injected i.m. (0.05
mg/kg) to reduce bronchial secretions. Before surgery, the
animal was treated with the analgesic Carprofen (Ry-
madil, 4 mg/kg, s.c.). Then, a continuous perfusion (0.1
ml/minute/kg) through an intravenous catheter placed in
the femoral vein with a mixture of 1% propofol (Fresenius)
and a 4% glucose solution (1 volume of propofol and 2
volumes of glucose solution) induced a deep and stable
anesthesia. The animal was then placed in a stereotaxic
headholder, using ear bars covered at their tip with local
anesthetic. Surgery was carried out under aseptic condi-
tions. The following parameters were monitored: heart
rate, respiration rate, expired CO2, arterial O2 saturation,
and body temperature. In early experiments, an extra i.v.
bolus of 0.5 mg ketamine diluted in saline (0.9%) was
added at potentially more painful steps of the surgical
procedure, such as laminectomy. In later experiments,
ketamine was added to the perfusion solution and deliv-
ered throughout surgery (0.0625 mg/minute/kg). With the











processes from C2 to Th1 were exposed. The paravertebral
muscles were retracted, and the laminae of segments C6,
C7, and Th1 were dissected. A complete C6 laminectomy
and an upper C7 hemilaminectomy were then performed.
The ligamentum ﬂavum was removed in order to expose
the dura mater, which was incised longitudinally. From
previously available anatomical material, the rostrocau-
dal level at which the dorsal rootlets entered, respectively,
cervical spinal segments 7 and 8 corresponded to the ros-
tral zone of the spinal cord covered by cervical lamina 6.
The dorsal root entry zone at the C7/C8 border was then
identiﬁed, providing a medial landmark for placing a sur-
gical blade (No. 11; Paragon), which was used to perform
an incomplete section of the cervical cord at this level. The
surgical blade was inserted 4 mm in depth perpendicular
to the spinal cord, and the section was prolonged laterally
to completely cut the dorsolateral funiculus. In most cases,
such a section completely interrupted the CS tract unilat-
erally. As illustrated in detail in a recent report (Freund et
al., 2006), the lesion was aimed at a site caudal to the
biceps motor nucleus but rostral to the nuclei of triceps,
forearm, and intrinsic hand muscles (Jenny and Inukai,
1983). The muscles and the skin were sutured. The animal
usually recovered from anesthesia 15–30 minutes after
interruption of the perfusion with propofol and was
treated postoperatively with an antibiotic (ampicilin 10%,
30 mg/kg, s.c.). During the week following the surgery,
additional doses of Carprofen were given daily (pills of
Rymadil mixed with food). After the spinal lesion, the
animal was kept alone in a separate cage for a couple of
days in order to perform a careful watch of its condition.
In addition, the transient separation in a cage allowed
better conditions for recovery than the usual group hous-
ing with other monkeys, into which the animal was usu-
ally replaced 2–5 days after surgery. Some of the behav-
ioral deﬁcits resulting from the lesion were described
previously (Freund et al., 2006) as well as the time course
of recovery observed with various motor tasks.
Anti-Nogo-A antibody treatment
The treatment lasted for 4 weeks, using either the anti-
Nogo-A antibody or control antibody (14.8 mg in 4 weeks)
delivered from an osmotic pump, placed in the back of the
animal a few minutes after the lesion of the cervical cord.
A small silastic tube, attached at one of its extremity to
the pump, was positioned intrathecally 3–5 mm rostral to
the cervical lesion. The pump had a volume of 2 ml, but
one or the other of two types of pumps were used, allowing
treatment during 4 or 2 weeks. In the latter case, after 2
weeks of treatment, the ﬁrst pump was replaced under
anesthesia by a second pump for another 2 weeks of treat-
ment. Seven monkeys received either one of two monoclo-
nal antibodies (mAbs) against different sites of Nogo-A
(Table 1): the mouse mAB 11C7 (Liebscher et al., 2005)
was raised against an 18-amino-acid peptide of rat Nogo-A
(aa 623–640), close to the most inhibitory region of the
Nogo-A protein (Oertle et al., 2003), which cross-reacts
with mouse and monkey Nogo-A. The second antibody
used, mAb hNogo-A, was raised by immunization with the
whole Nogo-A-speciﬁc region of the human Nogo-A se-
quence. The characterization of the two anti-Nogo-A anti-
bodies was performed as follows. Cynomologus monkey
brain tissue (cerebral cortex) was homogenized in T-PER
lysis buffer (Pierce, Rockford, IL) by using a rotor stator.
For Western blots, aliquots corresponding to 10 g total
protein were separated on a 4–12% NuPAGE gel (Invitro-
gen, Carlsbad, CA). The protein bands were transferred to
a nitrocellulose membrane. The membrane was blocked
for 1 hour at room temperature in blocking buffer [2%
blocking reagent (Amersham, Arlington Heights, IL) in
TBS-T], then incubated with either 0.1 nM hNogoA mAB
or 1 nM 11C7 antibody in blocking buffer for 2 hours,
followed by 1 hour of incubation with either anti-human or
anti-mouse peroxidase-coupled secondary antibodies (1:
500,000 dilution in blocking buffer). Signals were detected
with ECL-Advance Western Blot detection reagents (Am-
ersham) and exposure to ﬁlm for 1 minute. Both antibod-
ies recognize primate Nogo-A monospeciﬁcally on Western
blots (Fig. 1B; see also Oertle et al., 2003). The antibodies
were puriﬁed as IgGs and concentrated to 3–10 mg/ml in
phosphate-buffered saline (PBS). In the other six mon-
keys, a control antibody was infused, corresponding to a
puriﬁed IgG of a mouse mAb directed against wheat auxin
(AMS Biotechnology, Oxon, United Kingdom).
In safety studies conducted in the monkey, remaining
antibodies were retrieved from the pump at the end of the
treatment (after 4 weeks), when the osmotic pumps were
removed. The antibody hNogoA mAB was found to be
completely stable. Both anti-Nogo-A antibodies used were
shown to be distributed with the ﬂow of cerebrospinal ﬂuid
over most of the spinal cord and brain within 7 days of
infusion and to penetrate deeply into the parenchyma
(Weinmann et al., 2006). They are internalized together
with endogenous Nogo-A protein into endosomal and ly-
sosomal structures, leading to a down-regulation of
Nogo-A (Weinmann et al., 2006). The concentrations cho-
sen for the anti-Nogo-A antibody treatment (3–10 mg/ml)
are high in relation to the high-subnanomolar afﬁnities of
the antibody for Nogo-A. Therefore, differences in efﬁcacy
are not expected at these concentrations. Because of the
limited number of monkeys treated either with one (11C7)
or the other (hNogoA) of the two anti-Nogo-A antibodies,
the issue of whether there was a difference in efﬁcacy
between the two could not be addressed.
In the ﬁrst six lesioned monkeys included in the study
(pilot animals), the identity of the antibody contained in
the pump was known to the experimenters (Supplemen-
tary Table 1 in Freund et al., 2006). For the seven other
lesioned monkeys, the experimenters were blind to the
antibody contained in the pump (Supplementary Table 1
in Freund et al., 2006) until the end of the experiment
(killing of the animal and reconstruction of the lesion).
The pump and the silastic tube were removed after four
weeks of treatment. Each pump was then checked for the
volume left to ensure that the antibody had been properly
delivered.
Tracing experiments and histological
assessment of the lesion
The anterograde tracer biotinylated dextran amine
(BDA; Molecular Probes, Eugene, OR) was injected into
the contralesional hemisphere (motor cortex) of the 13
lesioned monkeys to label the CS tract, using Hamilton
syringes. Similarly, for comparison, BDA was injected uni-
laterally into the motor cortex of three additional intact
monkeys (Table 2). Under propofol anesthesia (see above),
a craniotomy was performed to expose the central and
arcuate sulci. Injections of BDA were performed in the
primary motor cortex (M1), i.e., in the rostral bank of the











hand representation. Based on previously available mon-
keys in which the hand representation was determined by
intracortical microstimulation (Rouiller et al., 1996, 1998;
Schmidlin et al., 2004, 2005), the hand territory was esti-
mated to be located immediately rostral to the central
sulcus, extending mediolaterally between 10 and 15 mm
from the midline, with its most lateral extent correspond-
ing roughly to the genu of the arcuate sulcus. In this
territory of about 5–6 mm along the mediolateral axis,
three to four syringe penetrations were aimed perpendic-
ularly to the cortical surface, at 1.5–2 mm distance from
each other. To cover most of the rostral bank of the central
sulcus, BDA was typically deposited along each syringe
penetration at two (rarely three) depths, usually at sites
located 3 and 7 mm below the pial surface. Usually one to
three additional syringe penetrations were performed
more medially, still along the central sulcus, to cover the
representation of more proximal territories (wrist, elbow,
shoulder, trunk). The detailed parameters of BDA injec-
tions are given for each monkey in Table 1. Based on our
previous experience with tracing the CS tract with BDA in
monkeys (Rouiller et al., 1996), the survival time after
BDA injection was set to 3 weeks for the ﬁrst two lesioned
animals. However, it turned out that the cervical lesion
substantially slowed the anterograde axonal transport of
BDA, so the tracer did not reach the cervical segments of
interest. For this reason, a much longer survival time
(around 60–80 days) was applied to the other 11 lesioned
monkeys, allowing transport of BDA up to the thoracic
level. Furthermore, it appeared that, in two lesioned mon-
keys, the BDA staining was not dense enough in the
cervical cord for a full anatomical analysis. Consequently,
these four animals (too short survival time or insufﬁcient
staining) were not considered further in the present study.
The list of the nine lesioned monkeys considered in the
present study for the analysis of CS axons rostral to the
cervical lesion is given in Table 1.
At the end of the survival period, the animals were
killed under deep (lethal) anaesthesia (90 mg sodium
pentobarbital/kg body weight) by transcardiac perfusion
with 0.9% saline (400 ml). The perfusion was continued
with ﬁxative (3 liters of 4% phosphate-buffered parafor-
maldehyde in 0.1 M phosphate buffer, pH 7.6) and solu-
tions (2 liters each) of the same ﬁxative containing in-
creasing concentrations of sucrose (10%, 20%, and 30%).
The brain and spinal cord were dissected and placed in a
30% solution of sucrose (in phosphate buffer) for cryopro-
tection for 7 days. Frozen sections (50 m thick) of the
brain were cut in the frontal plane, whereas frozen sec-
tions (50 m thick) of the cervical cord (approximately
segments C6–T3) were cut in the parasagittal longitudi-
nal plane and collected in three series for later histological
processing. Upper cervical segments and lower thoracic
spinal segments were cut in the frontal plane at 50 m
thick, and sections were also collected in three series. BDA
staining was revealed in one series of spinal cord sections,
as described in detail in previous reports (Rouiller et al.,
1996, 1998). The second series of spinal cord sections was
TABLE 1. List of the Lesioned Monkeys Included in the Present Study With Identiﬁcation Code1
Mk-CP Mk-CG Mk-CB Mk-CH Mk-AP Mk-AG Mk-AM Mk-AS Mk-AC
Species Fasc. Fasc. Fasc. Fasc. Fasc. Fasc. Fasc. Mul. Fasc.
Anti-Nogo-A
treatment










“Double-blind” procedure Yes Yes Yes Yes Yes No Yes No Yes


















Extent of hemicord lesion (%) 45 51 75 90 58 78 80 41 85
Extent of gray matter cut (%) 77 73 81 74 85 81 71 86 100
Number of BDA-labeled CS axons at C5 927 1,005 1,186 780 1,250 2,282 1,148 168 270
Percentage of uncrossed CS axons at C5 10 5 9 3 5 9 5 11 7
Volume of BDA injected (in l) 24 24 20 20 24 28 19 22 20
No. of BDA injection sites 12 12 10 10 12 15 10 11 10
Total No. of injection tracks 6 6 5 5 6 7 6 4 6
Survival time post-BDA injection (days) 78 70 78 62 81 70 69 72 64
No. of days between lesion and BDA injection 81 70 147 76 79 42 69 210 71
Age of the animal at sacriﬁce (years) 6.9 4 5 4 6.5 3.5 4 6.25 4
1) No. of retraction bulbs/No. of CS axons at C5 0.06 0.053 0.116 0.09 0.058 0.019 0.004 0.006 0.015
No. of CS axons with terminal bulbs 56 53 137 70 72 44 5 2 4


















Percentage of terminal retraction bulbs 100 m
rostral to the lesion
13 7 1 7 27 36 60 0 40
3) Normalized axon arbor length rostral to
lesion
41.624 14.961 35.769 23.33 41.914 71.12 64.752 — 31.307
4) Normalized No. of CS axotomized axons
entering lesion area
0.003 0.0039 0.0093 0.014 0.03 0.022 0.0366 — 0.0851
5) Normalized No. of CS axons going from
white to gray matter
0.135 — 0.111 0.128 0.213 0.301 0.169 — —
6) Normalized No. of CS axons crossing midline
at C5
0.045 0.028 0.025 0.041 0.06 0.06 0.05 — —
1Detailed information on the nine monkeys included in the present anatomical study. Eight of the nine monkeys were part of the previous report, describing the behavioral recovery
and the properties of the CS axon collaterals caudal to the lesion (Freund et al., 2006; see their Table 1). One additional animal (Mk-AG) was newly introduced in the present study.
At the time of the experiment, the monkeys had different names, not indicating whether the animal was infused with the control or the anti-Nogo-A antibody. Under species, Mul.
is for Macaca mulata and Fasc. is for Macaca fascicularis.The four control-antibody-treated monkeys (Anti-Nogo-A treatment: No) are in the four leftmost columns, whereas the
ﬁve anti-Nogo-A antibody treated monkeys are in the ﬁve rightmost columns (Anti-Nogo-A treatment: Yes) with indication of which of the two antibodies was used (mAB11C7 or
mAB hNogoA). Under Double-blind procedure, “yes” refers to monkeys for which the collaborators delivering the antibodies (control or anti-Nogo-A) did not know to which monkey
they were aimed for. On their side, the experimenters taking care of the monkeys did not know which antibody has been administered to the corresponding animal. In the row
Completeness of CS (dlf) section, “yes” and “no” indicate whether the dorsolateral funiculus (dlf) was or was not completely transected unilaterally, respectively. BDA in
parentheses means that completeness of the section of the dorsolateral funiculus unilaterally was assessed based on the BDA labeling of the CS tract immediately above the lesion.
If yes, this means that there was no BDA-labeled axon spared by the lesion in the aimed dorsolateral funiculus. If no, this means that few BDA-labeled axons in the dorsolateral
funiculus were spared by the lesion. For four animals, their age was not precisely determined when they were received in our animal facility and was estimated to be about 3 years











immunohistochemically processed to visualize corticospi-
nal axons by using the marker SMI-32, as recently re-
ported (Wannier et al., 2005), a series of sections also used
to reconstruct the location and extent of the cervical lesion
(Fig. 1C), as described in detail earlier (Schmidlin et al.,
2004; Wannier et al., 2005). The third series of sections
was processed to visualize another anterograde tracer
(dextran-ﬂuorescein) injected into the ipsilesional hemi-
sphere, but these data will not be presented here. A light
microscope (Olympus) and Neurolucida software were
used for analyses of CS axon numbers, retraction, arbor
length, sprouting, and trajectories.
Normalization of BDA-labeled CS axons
Because of variations in the uptake of BDA (Table 1; see
also Supplementary Table 1 in Freund et al., 2006), the
number of BDA-labeled CS axons varied from one animal
to the next. To normalize the BDA data across monkeys,
the total number of BDA-labeled CS axons was counted at
the C5 level on a frontal section in the white matter, in the
two dorsolateral funiculi, and in the ventral funiculus
ipsilateral to the BDA injection in the cerebral cortex
(Table 1).
Measurement of retraction of lesioned CS
axons and number of CS axons with
terminal retraction bulbs
On the photomicrographs of the parasagittal cervical
cord sections processed for BDA visualization, a ﬁrst line
was drawn along the rostral border of the lesion in Corel
Draw. A second line, parallel to the ﬁrst one, was drawn
600 m more rostrally, following the orientation of the
axons. The ﬁrst line offered a ﬁxed point of reference for
measuring the distance of CS axonal retraction (Fig. 2A).
The distance of the center of each terminal bulb (identiﬁed
as being at least twice the axon caliber) to the lesion
border was measured within this space. Only CS axons
with terminal bulbs located in the white matter at a max-
imal distance of 600 m from the edge of the lesion were
used for this analysis (Fig. 2A). A more speciﬁc question
was addressed to the terminal bulbs located in the ﬁrst
100 m from the rostral border of the lesion. CS axon
arbors displaying no such terminal bulbs were not taken
into consideration for measurement, because it could not
be excluded that the cut end of the axons was leaving the
plane of the section, thereby continuing on an adjacent
section. The cumulative number of CS axon with terminal
bulbs observed on the BDA sections analyzed was ﬁnally
divided by the total number of BDA-labeled CS axons
observed at C5, for normalization as explained above.
These assessments of the number of CS axons with termi-
nal retraction bulbs (Fig. 2D,F) and the distance of retrac-
tion (Fig. 2E) are represented schematically by the num-
bers 1 and 2 in Figure 1A.
Measurement of CS axon arborization and
CS sprouting
In the gray matter, the presence of BDA-labeled CS
axon arbors was investigated at the immediate border of
the lesion and within an area extending up to 500 m
away from the rostral limit of the lesion at a total magni-
ﬁcation of 200. For this analysis (schematically repre-
sented by the number 3 in Fig. 1A), all parasagittal spinal
cord sections processed for BDA visualization (150 m
intervals) on the ipsilesional cervical side were chosen. In
Neurolucida software, each BDA-labeled axon segment in
the gray matter was traced. Then, the cumulated axon
arbor length was computed and normalized with respect
to the total number of CS axons labeled at C5 level, as
described above.
By using Neurolucida as well, the BDA-labeled CS axon
arbors which attempted to enter the lesion by crossing the
rostral limit of the lesion were drawn. The accumulated
number of CS axon arbors intercepting the rostal border of
the lesion was determined in each monkey (analysis rep-
resented schematically by the number 4 in Fig. 1A).
To analyze further the sprouting of the CS axons in the
region rostral to the lesion, BDA-labeled CS axon arbors
entering into the gray matter were counted up to a dis-
tance of 3 mm away from the rostral border of the lesion on
the parasagittal sections (number 5 in Fig. 1A). For this
analysis, histological sections exhibiting BDA-stained CS
axons in the white and gray matter were selected (ranging
from ﬁve to nine slides across animals). At their crossing
with the white/gray matter border, these axon arbors were
generally oriented along a perpendicular axis, although
some of them showed an orientation that was slightly
oblique from the axis perpendicular to the white/gray mat-
ter border.
Furthermore, at more rostral levels in the cervical cord,
ﬁve frontal sections taken at C5 level were selected to
count the number of CS ﬁbers crossing the midline at C5
(analysis represented schematically by the number 6 in
Fig. 1A). In Neurolucida, a vertical line was superimposed
onto the midline of the frontal section of the cervical cord
at C5 level, and two additional vertical lines were drawn
at a distance of 250 m on each side away from the line on
the midline (see Fig. 5C). CS axon arbors crossing these
lines were counted (if the same axon arbor was long
enough to intercept two or three lines, it was counted
once) and the cumulative number for the ﬁve frontal sec-
tions was normalized by dividing by the total number of
CS axons present at C5 level in the white matter, as
described above.
For illustrations (see Figs. 2, 3, 5), photomicrographs
were captured from an Olympus microscope (BX40) in
Neurolucida and then stored as computer ﬁles for ﬁnal
processing in Corel Draw 12 or Corel Draw X3 software for
production of the ﬁnal montage. Contrast and brightness
adjustments were performed in Adobe ImageReady CS.
RESULTS
Morphology of the unilateral cervical cord
lesion
After unilateral injection of BDA into the contralesional
primary motor cortex (M1) mainly in the hand represen-
tation, the main CS tract was found at cervical cord level
C5 in the left dorsolateral funiculus, representing 90–95%
of the whole CS population (Fig. 1A). The uncrossed CS
projection (representing 5–10% of CS axons) was found in
the dorsolateral and ventral funiculi homolateral to the
BDA injection (Fig. 1A). These ﬁgures are consistent with
a recent report on the distribution of CS axons at the level
of the lumbar cord (Lacroix et al., 2004). The unilateral
section of the cervical cord was aimed at transecting the
crossed CS tract in the left dorsolateral funiculus (Fig.











Fig. 1. A: Schematic representation of the macaque monkey cor-
ticospinal (CS) projection originating from the right primary motor
cortex (M1) as seen at the cervical cord level, as a result of BDA
injection (green syringe) in the right motor cortex. At the C5 level, on
a frontal section of the cervical cord, green dots indicate the location
and distribution of the CS axons, forming the dorsolateral funiculus
(dlf) contralateral to the injection site, and the uncrossed CS axons,
present in the dorsolateral and ventral funiculi ipsilateral to the
injection site. At the C7/C8 level, the ensemble of black oblique lines
represents the cervical lesion performed in the present study in 13
monkeys. Rostral to the lesion, parallel thick green lines represent CS
axons in the dorsolateral funiculus, interrupted by the lesion. Axonal
sprouting is represented by thinner lines arising from the thick green
lines. The numbers 1–6 point to the six sites of the quantitative
analyses performed in the present study as explained in Materials
and Methods. The brown syringe is for pharmacological reversible
inactivation experiments of the contralesional primary motor cortex
(M1), as previously reported (Schmidlin et al., 2004) and mentioned in
the Discussion. The thick vertical dashed line represents the midline,
whereas the thin vertical dashed line represents the boundary be-
tween the white (wm) and the gray (gm) matter. A part of this
schematic has been published previously (Freund et al., 2006).
B: Both monoclonal antibodies against Nogo-A, 11C7 and anti-
hNogo-A, recognize a single band running at the expected molecular
weight of Nogo-A in cortex homogenates of adult macaque monkeys
separated by SDS-polyacrylamide gel electrophoresis. C: Reconstruc-
tion from parasagittal sections in the frontal plane of the location and
extent of the lesion at C7/C8 lesion performed in the nine monkeys
included for the present analysis of the CS tract rostral to the lesion.
Lesions in blue are for the control antibody treated monkeys (n  4),
whereas red represents the lesion in the anti-Nogo-A antibody treated
monkeys (n  5). The asterisks indicate the two monkeys with incom-
plete lesion of the dorsolateral funiculus (see text). Among the nine






















present anatomical analysis, the dorsolateral funiculus
was indeed completely interrupted, as assessed on the
basis of the location and extent of the lesion (Fig. 1C) in
comparison with the location and extent of the dorsolat-
eral funiculus in an intact monkey after BDA injection in
M1. In addition, BDA labeling of CS axons in the white
matter provided evidence that all axons in the dorsolat-
eral funiculus were indeed sectioned in these seven mon-
keys. On the other hand, in two monkeys (indicated by an
asterisk in Fig. 1C), the lesion did not completely inter-
rupt the dorsolateral funiculus in its most ventrolateral
extent, so some CS ﬁbers were spared. The intact BDA-
labeled CS ﬁbers were easily detectable because of their
straight course in the white matter; these were excluded
from the anatomical analysis. The lesion territory was
easily distinguishable from the intact spinal cord tissue. A
scar consisting of nonhomogenous tissue and of cysts of
various diameters was observed, acting as a clear physical
impediment for axonal regrowth in the rostrocaudal direc-
tion (Fig. 3A).
Effects of anti-Nogo-A antibody treatment
on CS axons in the region rostral to the
cervical cord lesion
To evaluate whether the anti-Nogo-A antibody treat-
ment favored the maintenance, growth, and/or sprouting
from the CS axons in the area rostral to the cervical cord
lesion, six quantitative morphological analyses were con-
ducted at speciﬁc locations, represented schematically by
the numbers 1–6 in Figure 1A and presented below in the
following six sections. The detailed results obtained for
these six analyses are given for each individual lesioned
monkey in Table 1.
Appearance and number of terminal retraction
bulbs on transected BDA labeled CS axons. In all
monkeys subjected to cervical cord lesion, BDA-labeled CS
axons displaying terminal retraction bulbs were found
rostral to the lesion (Fig. 2A–C), corresponding to a com-
mon feature for transected axons that underwent retro-
grade degeneration (Kalil and Schneider, 1975; Kao et al.,
1977a,b; Houle and Jin, 2001). To investigate the inﬂu-
ence of anti-Nogo-A antibody treatment on the transected
CS axons, the region rostral to the lesion was scanned at
high magniﬁcation for CS axons exhibiting terminal re-
traction bulbs.
Terminal retraction bulbs in the area rostral to the
lesion, in a territory of white matter extending 600 m
away from the lesion border, were counted in each monkey
and accumulated for all parasagittal sections analyzed.
For normalization, the accumulated numbers of terminal
retraction bulbs in each monkey were divided by the total
number of BDA-labeled CS ﬁbers in the white matter at
C5 level. Strikingly, in anti-Nogo-A antibody treated mon-
keys, the normalized cumulated numbers of CS axons
exhibiting terminal retraction bulbs were signiﬁcantly
lower (approximately fourfold on average) than in control
antibody treated monkeys (Fig. 2D). This difference was
statistically signiﬁcant (Mann and Whitney test, P 
0.05). Furthermore, from a qualitative point of view, anti-
Nogo-A antibody treated monkeys, instead of exhibiting
the standard terminal retraction bulbs, often showed out-
growing sprouts being tortuous in shape and decorated
with varicosities, strongly resembling boutons en passant
and terminaux that approached the lesion border (Fig.
3B,C).
CS axonal retraction (axonal dieback). To address
the issue of a response of the transected CS axons to
anti-Nogo-A antibody treatment, the distance of retrac-
tion from the lesion for the CS axons exhibiting a terminal
retraction bulb was measured. All terminal retraction
bulbs within a distance of 600 m from the rostral limit of
the lesion were included.
The average retraction distance from the lesion border
was markedly reduced in anti-Nogo-A antibody treated
monkeys compared with the control antibody treated mon-
keys (Fig. 2E). This difference was not statistically signif-
icant (Mann and Whitney test, P  0.05). However, be-
cause of the large variability across monkeys and because
of the much lower number of CS axons with terminal
retraction bulbs in the anti-Nogo-A antibody treated mon-
keys with regard to that in the control antibody treated
monkeys, the conditions were not favorable for detecting a
possible treatment-induced population difference (Fig.
2E).
A prominent difference appeared, however, when we
focused on a more restricted area, within 100 m of the
rostral limit of the lesion (Fig. 2F). About 10% of
transected CS axons displaying a terminal retraction bulb
were found in the control antibody treated monkeys. In
contrast, this proportion ranged between 27% and 60% in
the anti-Nogo-A antibody treated monkeys (see also Table
1). Insofar as the total number of terminal retraction
bulbs was much higher in the control antibody treated
monkeys (Fig. 2D), the data in Figure 2F indicate that the
transected CS axons in anti-Nogo-A antibody treated
monkeys rarely formed terminal retraction bulbs, but,
when they did, they were located close to the lesion. In
contrast, the numerous terminal retraction bulbs in the
Fig. 2. A–C: A displays transected BDA-labeled CS ﬁbers at the
proximity of the rostral border of the lesion in the white matter. The
lesion border appears as nonhomogenous axon-free tissue distinct
from more rostral intact spinal cord tissue. The arrows with double
heads illustrate how the distance was measured between a terminal
retraction bulb and the rostal border of the lesion. L, lesion; wm, white
matter. B and C illustrate at higher magniﬁcation BDA-labeled CS
axons close to the lesion forming retraction bulbs (arrows). D: Nor-
malized number of terminal retraction bulbs observed within a terri-
tory extending 600 m away from the lesion border in the rostral
direction for the nine lesioned monkeys included in the present study,
separately for the control antibody treated monkeys (n  4) and the
anti-Nogo-A antibody treated monkeys (n  5). The site of this anal-
ysis is schematically represented by the number 1 in Figure 1A. E: For
each monkey, the distance between each terminal retraction bulb
observed and the rostal limit of the lesion was plotted. Superimposed
on the individual measurements, the box and whisker plot depicts the
median value (horizontal bar in the middle of the box) and the 25th
and 75th percentiles (bottom and top extremities of the box, respec-
tively). The site of this analysis is schematically represented by the
number 2 in Figure 1A. F: Instead of considering a territory of 600 m
away from the lesion in the rostral direction (A,D,E), a more restricted
area only 100 m away from the lesion was considered. The horizontal
bar represents the percentage of the total number of terminal retrac-
tion bulbs observed up to 600 m away from the lesion, which termi-
nates not farther than 100 m from the rostral border of the lesion.











control antibody treated monkeys had generally retracted
farther from the lesion.
Density of CS axon arbors in the gray matter rostral
to the lesion. To investigate whether anti-Nogo-A anti-
body treatment induced changes within the gray matter of
the cervical cord above the lesion, the BDA-labeled CS
axon arbors within the spinal cord 500 m rostral to the
lesion on parasagittal sections were traced bilaterally at a
magniﬁcation of 200. The sections were then superim-
posed (Fig. 4A–D), showing for each animal the density of
axon arbors in the white matter rostral to the lesion
(brown lines) as well as in the gray matter rostral to the
lesion (black lines on the left side of the lesion shown in
Fig. 4A–D). For completeness of the information, BDA-
labeled CS axon arbors caudal to the lesion were also
represented. However, these data were described in a
recent report (Freund et al., 2006) and will therefore not
be considered further. At ﬁrst sight, numerous BDA-
labeled CS axon arbors are present in the gray matter
rostral to the lesion (Fig. 4A–D), without obvious differ-
ences between the two groups of monkeys. To quantify the
density of CS axon arbors in the gray matter rostral to the
lesion, their cumulative length was measured (see Mate-
rials and Methods). The cumulative axon arbor length was
then normalized by dividing by the total number of BDA-
labeled CS axons present at C5 level in the white matter
and plotted as a function of the extent (in percentage of
the hemicord) of the lesion (Fig. 4E). If one excludes the
animal Mk-CP (asterisk in Fig. 4E), which had an incom-
plete lesion of the CS tract, there is a clear trend showing
that anti-Nogo-A antibody treated monkeys (red squares
in Fig. 4E) displayed a higher accumulated axon arbor
length than the control antibody treated monkeys (blue
circles), thus indicating that the anti-Nogo-A antibody
treatment enhanced axon sprouting in the gray matter
rostral to the cervical lesion. However, this trend was not
statistically signiﬁcant (Mann and Whitney test, P 
0.05).
More labeled CS axon arbors are visible rostral and
caudal to the lesion in Mk-CG (control antibody treated)
than in Mk-AC (anti-Nogo-A antibody treated); this ap-
parent contradiction is due to the much higher (fourfold)
total number of CS axons labeled with BDA in Mk-CG
than in Mk-AC (see Table 1). If normalized according to
the total number of CS axons labeled with BDA, then
Mk-AC exhibits a larger cumulative axon arbor length
rostral to the lesion (Fig. 4E) and a higher number of axon
swellings caudal to the lesion (Fig. 4F) than Mk-CG (see
also Freund et al., 2006). Furthermore, the extent of the
lesion was smaller in Mk-CG than in Mk-AC.
CS axon arbors entering the lesion. On the parasag-
ittal reconstructed sections used for the CS axon arbor
length measurements, special attention was paid to CS
axon arbors entering the scar tissue of the lesion. Exam-
ples are shown in Figure 5A, where more CS axons en-
tered the lesion in three anti-Nogo-A antibody treated
monkeys (red) than in one control antibody treated mon-
key (blue). For quantiﬁcation, BDA-labeled CS axon ar-
bors that crossed the rostral border of the lesion were
counted in each monkey, normalized (according to the
total number of BDA-stained CS axons at C5), and com-
pared between the two groups of monkeys (Fig. 5D). All
anti-Nogo-A antibody treated animals exhibited a higher
number of CS axon arbors entering the scar tissue than
the highest number of such axons found in the group of
Fig. 3. A: Photomicrograph of a parasagittal spinal cervical-
thoracic cord section illustrating the appearance of BDA-labeled CS
ﬁbers in the gray matter, rostral to the lesion (arrow). The section was
taken from an anti-Nogo-A antibody treated monkey. The CS axons in
the white matter and the CS axon arbors in the gray matter, shown at
higher magniﬁcation in B and C, are located in the cervical cord as
indicated by the two rectangles. B,C: Typical examples of sprouting
from transected CS axons in the white matter (B) and gray matter (C)
giving rise to collaterals directed toward the lesion border. These
axons were tortuous and irregular in growth, with varying diameter
and varicosities (arrows) along their course and at their termination.
wm, White matter; gm, gray matter. Scale bars  1 mm in A; 100 m











control monkeys (Fig. 5D, Table 1). This difference be-
tween the two groups of monkeys is statistically signiﬁ-
cant (Mann and Whitney test, P  0.05). Typically, the
course of these ﬁbers was highly irregular, showing that
they were regenerating rather than surviving ﬁbers. Nev-
ertheless, even in anti-Nogo-A antibody treated monkeys,
the number of CS axons entering the lesion remains very
low (Fig. 5D). Furthermore, none of these CS ﬁbers
reached the caudal border of the lesion. These results
indicate that the CS axon arbors observed caudal to the
lesion (Freund et al., 2006) did not arise from transected
CS axons, which would have regenerated straight through
the lesion but rather from regenerating axons having
grown around the lesion on bridges of spared white and
gray matter.
CS axon collaterals entering the gray matter rostral
to the cervical lesion. To determine whether anti-
Nogo-A antibody treatment possibly enhanced CS axon
collateral sprouting, the number of axon arbors leaving
the cervical white matter and entering the gray matter
was counted in the two groups of monkeys. Axons were
counted within a territory extending as far as 3 mm ros-
tral from the lesion (Figs. 1A, 5B). Only six monkeys
(Mk-CB, Mk-CH, Mk-CP, Mk-AP, Mk-AM, and Mk-AG)
fulﬁlled the criterion of sufﬁcient quality of BDA staining
to identify clearly such CS axon arbors leaving the white
matter and entering the gray matter. The number of such
CS axon arbors was normalized and plotted as a function
of the extent of the hemicord lesion (Fig. 5E). The number
of CS axon arbors passing from the white to the gray
matter was lower in the three control antibody treated
monkeys than in the three anti-Nogo-A antibody treated
monkeys, without any obvious relationship to lesion size
in either group of monkeys (Fig. 5E). For comparison,
the same measurement was made in an intact mon-
key (Mk-I3; Table 2), exhibiting a normalized number of
CS axon arbors entering the gray matter rostral to the
lesion slightly lower than that for the three control anti-
body treated monkeys subjected to cervical cord lesion
(Fig. 5E).
CS axons crossing the midline at C5. In the case of
complete hemisection of the spinal cord, CS axons growing
around the lesion in an attempt to reinnervate the dener-
vated spinal cord caudal to the lesion would have to cross
the spinal cord midline. For this reason, we examined the
frontal sections taken at level C5 to determine whether
BDA-labeled CS axons crossed the midline in the gray
matter and whether such midline crossing was enhanced
by the anti-Nogo-A antibody treatment (Fig. 5C; see also
Materials andMethods). The sum of CS axons crossing the
midline at C5 in each monkey was normalized to the total
number of labeled CS axons and plotted as a function of
the lesion extent (Fig. 5F). The anti-Nogo-A antibody
treated monkeys exhibited a higher number of midline
crossing CS axons than the control antibody treated mon-
keys (Fig. 5F). There was no relationship to the lesion
extent in either group of monkeys. For comparison, the
same analysis was conducted in three intact monkeys
(Table 2), exhibiting a normalized number of CS axons
crossing the midline at C5 equal or lower than the four
control antibody treated monkeys subjected to cervical
cord lesion (Fig. 5F).
DISCUSSION
The present study provides evidence that, after unilat-
eral cervical lesion that sections the dorsolateral funicu-
lus, anti-Nogo-A antibody treatment decreases the nor-
mally occurring retrograde degeneration of the CS
axotomized axons: the number of terminal retraction
bulbs formed by the axotomized CS axons was smaller in
the group of anti-Nogo-A antibody treated monkeys than
in the group of control antibody treated monkeys (Fig. 2D),
and the terminal retraction bulbs were closer to the lesion
(Fig. 2E,F). Thus, anti-Nogo-A antibody treatment pre-
vented to some extent the phenomenon of axonal dieback.
More CS axons grew into the lesion scar, but their regen-
eration through the scar tissue remained unsuccessful. In
contrast, increased numbers of CS axon arbors were seen
in the anti-Nogo-A antibody treated spinal cord rostral to
the lesion. Some of these ﬁbers arborized in the spinal cord
caudal to the injury, as recently reported (Freund et al.,
2006).
With respect to the question of direct regeneration of the
cut stem axon or collateral axonal sprouting, there is
evidence here that both were enhanced by anti-Nogo-A
antibody treatment. Axotomized CS axons growing and
penetrating into the lesion area were more numerous in
the anti-Nogo-A antibody treated monkeys than in the
control antibody treated ones. However, none of the CS
axons penetrating the scar seemed to be able to reach its
distal end. Scar-associated growth inhibition factors prob-
ably account for this blockade of regeneration (Rhodes and
Fawcett, 2004).
CS axons rostral to the injury gave rise to collaterals.
The anti-Nogo-A antibody treatment enhanced the pres-
ence of CS axon arbors in the gray matter rostral to the
lesion, the number of CS axon arbors (possibly correspond-
ing to CS axon collaterals) passing from the white to the
gray matter, and ﬁnally the number of CS axon arbors
crossing the segmental midline at the C5 level. These
measurements show that axonal sprouting took place ros-
tral to the cervical lesion, and that some of these ﬁbers
were in position to grow around the lesion in order to
reinnervate the spinal cord territory caudal to the lesion
deprived of CS input. The anti-Nogo-A antibody treatment
enhanced CS axonal sprouting and regrowth, conﬁrming
previous observations in anti-Nogo-A antibody treated
rats (Liebscher et al., 2005).
The larger number of CS axon arbors observed caudal to
the lesion in the anti-Nogo-A antibody treated monkeys
correlates with enhancement of functional recovery, espe-
cially of manual dexterity, i.e., functions known to depend
on direct inputs from CS ﬁbers (Freund et al., 2006). As
discussed further below, in our view the present data
suggest a mechanism of functional recovery relying on
collateral sprouting that arises from the axotomized CS
axons rostral to the lesion, possibly contributing to the
increased presence of CS axonal arbors in the gray matter
of the spinal segments caudal to the lesion (green curved
lines in Fig. 1A). Again, these data are consistent with
previous data in rodents showing that “regenerative
sprouting” enhanced in anti-Nogo-A antibody treated rats
consisted of CS collaterals growing around the lesion on
remaining tissue bridges (see, e.g., Von Meyenburg et al.,























The present study did not address the possibility that
some CS axon arbors observed caudal to the lesion
(Freund et al., 2006) could result from sprouting arising
from the undecussated CS axons not affected by the cer-
vical lesion (Fig. 1A). In rats subjected to a spinal cord
lesion interrupting the main CS tract, axon sprouting
from the intact ventral CS tract was indeed found to play
an important role in the spontaneous postlesion recovery
(Weidner et al., 2001). CS ﬁbers from the intact side have
been seen to cross the spinal cord midline in rats after
unilateral pyramidotomy and anti-Nogo-A antibody appli-
cation (Thallmair et al., 1998). In earlier studies in ma-
caques, we found that reversible inactivation by intracor-
tical muscimol infusion in the contralesional hemisphere
several months postlesion leads to a loss of recovered
manual dexterity (Schmidlin et al., 2004; see brown sy-
ringe in Fig. 1A). In contrast, reversible inactivation of the
ipsilesional hemisphere in control antibody treated mon-
keys did not affect the postlesional functional recovery
(Schmidlin et al., 2005), indicating that the decussated CS
tract originating from the ipsilesional hemisphere does
not play a major role in the recovery. Altogether, the
present data as well as our recent report (Freund et al.,
2006) favor the notion that collateral sprouting and
growth of the axotomized CS tract after cervical cord le-
sion may play a role in the postlesion functional recovery.
It remains to be determined whether other descending
tracts (rubrospinal, reticulospinal, long propriospinal pro-
jections) might also contribute, as shown in the rat (see,
e.g., Hashimoto and Fukuda, 1991; Feraboli-Lohnherr et
al., 1997; Raineteau et al., 2001; Fouad et al., 2001;
Schucht et al., 2002; Ruitenberg et al., 2003; Bareyre et
al., 2004). The possibility that the rubrospinal and reticu-
lospinal tracts may play a role in the functional recovery is
consistent with the observation reported by Freund et al.
(2006) that the two control antibody treated monkeys with
a lesion leaving intact a signiﬁcant portion of these two
tracts spontaneously recovered much better than the con-
trol antibody treated animal in which the lesion inter-
rupted these two tracts completely.
The correlation between the anti-Nogo-A antibody en-
hancement of CS sprouting rostral to the cervical lesion
(present study) and the density of CS tract axons caudal to
the lesion (Freund et al., 2006) is shown in Figure 4F. The
normalized cumulative axon arbor length as determined
rostral to the lesion (present study) was plotted as a func-
tion of the normalized number of CS axonal swellings
found caudal to the lesion, as reported recently (Freund et
al., 2006). The control antibody treated monkeys subjected
to complete transection of the dorsolateral funiculus ex-
hibited no or only few CS axonal swellings caudal to the
lesion; this was correlated with limited axonal sprouting
rostral to the lesion in these animals (Fig. 4F, three blue
circles on the left of the plot). In sharp contrast, the four
anti-Nogo-A antibody treated monkeys, all subjected to
complete transection of the dorsolateral funiculus, exhib-
ited much higher numbers of CS axonal swellings caudal
to the lesion. This again correlated with a signiﬁcantly
higher density of CS axon arbors arising from sprouts
rostral to the lesion (red squares in Fig. 4F). The control
antibody treated monkey Mk-CP (asterisk in Fig. 4F) has
to be considered separately, because the lesion of the dor-
solateral funiculus was incomplete (Fig. 1C), leaving in-
tact a small bundle of CS axons. The intact CS axons
reaching the region caudal to the lesion sprouted profusely
at that level, giving rise to numerous axon arbors and
swellings. This animal showed a much better functional
recovery than the other control antibody treated monkeys
(Freund et al., 2006).
COMPARISON WITH PREVIOUS STUDIES
The present model of cervical cord lesion in the monkey
can be compared, at least from a behavioral point of view,
with previous studies in which macaque monkeys were
subjected to a lesion of the cervical cord (Galea and
Darian-Smith, 1997; Sasaki et al., 2004). Although the
transection of the dorsolateral funiculus was aimed at
lower cervical segments (C7/C8) than in these two studies
(C3–C4), we observed an extent and a time course of
functional recovery (Freund et al., 2006) largely compara-
ble to that reported by Galea and Darian-Smith (1997). In
contrast, Sasaki et al. (2004) reported an even faster, if not
immediate, time course of recovery of precision grip and
independent ﬁnger movements (1–28 days), although
weakness in force and deﬁcit in preshaping lasted longer.
The two studies of lesions at the C3–C4 level (Galea and
Darian-Smith, 1997; Sasaki et al., 2004) did not analyze
the plasticity of the CS tract in the vicinity of the cervical
lesion, thus preventing a comparison with the present
anatomical data.
A different neutralizing antibody against Nogo-A,
mAbIN-1, was applied in marmosets with a thoracic lesion
(Fouad et al., 2004). CS ﬁbers growing around the lesion
Fig. 4. A–D: Superimposed reconstructions of parasagittal sec-
tions of the cervical-thoracic cord showing the lesion (vertical arrow)
as well as the density of BDA-labelled CS axon arbors present around
the lesion, in four different monkeys (with a reminder of their lesion
extent). Two monkeys received the control antibody (Mk-CH and
Mk-CG in A and C), whereas in the other two monkeys the anti-
Nogo-A antibody was delivered (Mk-AM and Mk-AC in B and D).
Rostral to the lesion, the densely packed brown line segments repre-
sent the BDA-labelled CS axons in the white matter, interrupted by
the transection of the dorsolateral funiculus. The position of the
rostral stump of CS ﬁbers in the white matter and of the axon arbors
in the gray matter is schematic, as derived from a superimposition of
sections, some of which were located more lateral than those for which
their contour is represented here. The black line segments represent
the CS axon arbors traced rostrally in the gray matter and caudally to
lesion. In these four monkeys, the dorsolateral funiculus was com-
pletely transected. A less extended version of these four reconstruc-
tions has been previously published by Freund et al. (2006), which
contained at that time only the axon arbors in the gray matter caudal
to the lesion. Here, the reconstructions have been extended to repre-
sent also the CS axon arbors rostral to the lesion, which are the topic
of the present report. E: Relationship between the normalized cumu-
lated axon arbor length in the gray matter rostral to the lesion as a
function of the extent (in percentage) of the hemicord lesion. Cumu-
lated axon arbor lengths were measured only rostral to the lesion.
Blue circles are for control antibody treated monkeys, whereas red
squares are for the anti-Nogo-A antibody treated monkeys. The site of
this analysis is schematically represented by the number 3 in Figure
1A. F: The present data on the axonal sprouting of the CS tract rostral
to the lesion (reﬂected here by the normalized cumulated axon arbor
length) were plotted as function of the normalized number of CS
axonal swellings observed caudal to the lesion, as reported recently





















and into the caudal spinal cord were observed (Fouad et
al., 2004), but the animals were not tested behaviorally,
preventing correlation with functional recovery.
A postlesion sprouting of the CS tract was shown to be
present in hamster only at perinatal ages (Kuang and
Kalil, 1990). Adult hamsters subjected to pyramidotomy
exhibited a retraction of the axons rostral to the lesion by
a substantial distance, up to about 6–7 mm after several
months. The present data, derived from macaque mon-
keys subjected to cervical lesion, are markedly different
because the distance of retraction was much smaller. In-
deed, after 4–6 months postinjury, most terminal retrac-
tion bulbs were located not more than 1 mm from the
lesion. Furthermore, in the marmoset as well, the termi-
nal retraction bulbs appeared to be located close to the
lesion after 2 weeks postinjury (Fouad et al., 2004). These
data are in line with earlier reports in monkey and man
that retrograde degeneration of axotomized CS axons was
limited to the region immediately above the lesion (Tower,
1940; Bronson et al., 1978). In rats, axonal dieback follow-
ing spinal cord lesion was studied for the rubrospinal and
reticulospinal tracts (Houle and Jin, 2001). The authors
observed an average retraction of the axons over a mean
distance of about 500 m, which is of the same order as
the retraction of the CS axons seen in monkeys (Fouad et
al., 2004; present study). The limited axonal dieback is
thus favorable for a regenerative sprouting from the axo-
tomized axons, giving rise to collaterals that can grow in
the caudal direction around the lesion in order to reinner-
vate the region caudal to the lesion.
In the present study, young adult monkeys (3.5–6.9
years old at time of death) were subjected to spinal cord
lesion (Table 1). It cannot be excluded that some of the
axonal sprouting (although limited) observed in the con-
trol antibody treated monkeys occurred because of the
relatively juvenile state of some of the animals and would
not have taken place in older animals. Similarly, it is not
established whether the enhancement of sprouting result-
ing from the anti-Nogo-A treatment would have reached
the same extent in older animals. Nevertheless, most of
our animals (except maybe Mk-AG) had an age at the time
of the lesion (3.5 years or more) by which the myelination
of the CS tract reached the adult stage, insofar as full
myelination was reported to last for as long as 36 months
(Olivier et al., 1997). As far as the CS tract is concerned,
the animals included in the present study can thus be
considered as adult monkeys.
As a result of BDA injection in M1, the number of
CS-labeled axons observed at the C5 level on transverse
sections (up to 2,282; see Table 1) appears low considering
that the total number of CS axons was estimated to be
400,000 and that the number of CS neurons retrogradely
labeled after tracer injection in the upper spinal cord
amounted to 72,000 in the entire frontal lobe (Dum and
Strick, 1991). There are a number of possible explanations
for this result. First, only 50% of the precentral CS axons
originate from M1 (Dum and Strick, 1991; He et al., 1993,
1995). Second, the BDA injections formed patchy territo-
ries, leaving in-between zones where there was no or less
uptake. Third, the BDA injections did not cover the entire
M1. Fourth, a contingent of CS axons terminates above
C5. In addition, BDA infusion was limited to the rostral
bank of the central sulcus; therefore, the whole rostral
part of M1 was not injected. Furthermore, compared with
TABLE 2. List of the Three “Intact” Monkeys Included in the Present
Study With Identiﬁcation Code1
Mk-I1 Mk-I2 Mk-I3
Species Fasc. Fasc. Fasc.
Age at death (years); weight (kg) 4; 5 8.3; 10 7.7; 10
Volume of BDA injected (in l) 10 22.5 25.5
No. of injection sites 7 15 17
No. of injection tracks 3 9 11
Survival time postinjection (days) 25 42 48
Normalized No. of CS axons going from
white to grey matter
—2 —3 0.078
Normalized No. of CS axons crossing
midline at C5
0.02 0.021 0.025
No. of CS axons in the white matter at C5
(for normalization)
1,766 984 1,922
No. of crossed CS axons at C5 (% of total) 1,620 (91.7) 859 (87.3) 1,735 (90.3)
No. of uncrossed CS axons at C5 (% of
total)
146 (8.3) 125 (12.7) 187 (9.7)
1The data in italics derived from these three intact (unlesioned, untreated) animals
were used to establish a baseline for the analyses presented for the lesioned repre-
sented monkeys in Figure 5E,F. In the two intact monkeys (Mk-I2 and Mk-I3), injection
of tracer into the motor cortex was the unique intervention, following the protocol
described in Materials and Methods. Mk-I1 was used in a previous tracing study
(Rouiller et al., 1996), in which the primary motor cortex was mapped by using
intracortical microstimulation before BDA injection. Under species, Fasc. is for Macaca
fascicularis. 2In Mk-I1, the cervical segment C6-T3 was not cut in the sagittal plane
(but in the frontal plane),so the assessment of the number of axons entering the gray
matter could not be made. 3In Mk-I2, the quality of the BDA reaction at C6-T3 did not
allow the assessment of the number of axons entering the gray matter. In contrast, the
block including C5 (sectioned in the frontal plane) was processed separately, and the
BDA reaction allowed the determination of the number of CS axons crossing midline.
Fig. 5. A: Reconstructions of one parasagittal section of the
cervical-thoracic cord for each monkey, showing the lesion at C7/C8
(gray area) as well as the BDA-labeled CS axon arbors present rostral
to the lesion (up to a distance of 500 m from the lesion) in four
monkeys. For three anti-Nogo-A antibody treated monkeys (Mk-AM,
Mk-AP, Mk-AC), the CS axon arbors were drawn in red, whereas, for
one control antibody treated monkey, they were drawn in blue.
B: Photomicrograph of a parasagittal cervical cord, showing the re-
gion rostral to the lesion where numerous BDA-labeled CS axons and
axon collaterals are present in the white and gray matter. The black
line delineates the border between gray and white matter. CS axon
arbors crossing this line (mainly in a perpendicular orientation) were
counted and normalized by dividing their cumulative sum across
sections by the total number of CS axons labeled at C5 level. C: Pho-
tomicrograph of a cervical spinal cord frontal section taken at the C5
level showing at higher magniﬁcation the central part of the cervical
cord, with some CS axons crossing the midline and terminating in the
opposite gray matter. CS collaterals intercepting one of black vertical
lines were counted, and the cumulative number was normalized by
dividing it by the total number of labeled CS ﬁbers. D: Normalized
number of BDA-labeled CS axon arbors crossing the rostral border of
the lesion in order to enter into the lesion area. The site of this
analysis is schematically represented by the number 4 in Figure 1A.
E: The normalized cumulated number of CS axon arbors crossing the
white/gray matter border along an axis perpendicular to this border
(see Fig. 5B) was plotted as a function of the extent of the hemicord
lesion (in percentage). Blue circles are for control antibody treated
monkeys, whereas anti-Nogo-A antibody treated monkeys are repre-
sented by a red square. Data derived from an intact monkey are
shown by a black triangle. The site of this analysis is schematically
represented by the number 5 in Figure 1A. F: The normalized number
of CS axon collaterals crossing the midline at the C5 level (see Fig. 5C)
was plotted as a function of the extent of the hemicord lesion (in
percentage). Blue circles are for control antibody treated monkeys,
whereas anti-Nogo-A antibody treated monkeys are represented by a
red square. Data derived from three intact monkeys are shown by
black triangles. The site of this analysis is schematically represented











uptake of other anterograde tracers, such as WGA-HRP,
the uptake of BDA appears less prominent. However, to
explain the surprisingly low number of CS axons labeled
with BDA in the present study, one may consider the
likely possibility that the very ﬁne axons making up the
majority of the CS tract are not labeled or escaped detec-
tion at the light microscopic level, as suggested by our
observation that most BDA-labeled CS axons visible in
our material at the C5 level are relatively large in diam-
eter. In this context, for the same reason, one cannot
exclude that some ﬁne CS axons unlabeled with BDA or
undetected at the light microscopic level were spared by
the lesion.
In conclusion, the present study demonstrates quanti-
tatively that anti-Nogo-A antibody treatment attenuated
the retraction of axotomized CS axons after cervical cord
injury and enhanced axonal sprouting rostral to the le-
sion. Within the scar tissue, growth of these ﬁbers is
blocked by inhibitory factors other than Nogo-A. Some
ﬁbers, however, succeeded in bypassing the scar, presum-
ably by remaining on gray matter bridges. These axons
growing around the lesion probably make an important
contribution to the incomplete but signiﬁcantly enhanced
reconstruction of the CS ﬁber plexus caudal to the lesion
in the anti-Nogo-A antibody treated monkeys (Freund et
al., 2006), moreso than the ﬁbers attempting to regenerate
and to reenter the lesion itself. The contingent of CS axons
growing around the lesion in the gray matter is believed to
be an anatomical correlate of the functional recovery ob-
served in the anti-Nogo-A antibody treated animals.
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